SEC Form 4	
------------	--

Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVA

IAL OWNERSHIP		VAL
IAL OWNERSHIP	OMB Number:	3235-0287
IAL OWNERSHIP	Estimated average burd	en
nge Act of 1934	hours per response:	0.5
t of 1040	L	

STATEMENT	OF	CHANGES	N	BENEFICIAL	OWNERSH

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

			or Section 30(n) of the investment Company Act of 1940				
1. Name and Addro Troendle Au		g Person [*]	2. Issuer Name and Ticker or Trading Symbol <u>Medpace Holdings</u> , Inc. [MEDP]		ationship of Reporti k all applicable) Director	ng Pers X	son(s) to Issuer 10% Owner
(Last) (First) (Middle) C/O MEDPACE HOLDINGS, INC.		()	3. Date of Earliest Transaction (Month/Day/Year) 02/29/2024	X	Officer (give title below) CEO		Other (specify below)
5375 MEDPAC	CE WAY		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indi Line)	vidual or Joint/Grou	p Filing	(Check Applicable
(Street)				X	Form filed by Or	e Repc	orting Person
CINCINNATI	ОН	45227			Form filed by Mo Person	re than	One Reporting
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication				
			Check this box to indicate that a transaction was made pursuant satisfy the affirmative defense conditions of Rule 10b5-1(c). See	to a contr Instruction	act, instruction or writ n 10.	ten plan	that is intended to

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	02/29/2024		S ⁽¹⁾		20,000	D	\$393.71(2)	5,113,019	Ι	By Medpace Investors, LLC ⁽³⁾
Common Stock	03/01/2024		S ⁽¹⁾		80,000	D	\$401.88 ⁽⁴⁾	5,033,019	Ι	By Medpace Investors, LLC ⁽³⁾
Common Stock								806,643	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of E		6. Date Exerc Expiration Da (Month/Day/Y	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period.

2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$390.41 to \$401.90. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

3. The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be

deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

4. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$400.00 to \$404.88. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

Remarks:

/s/ Stephen P. Ewald,

Attorney-in-Fact for August J. 03/04/2024

Troendle

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.